At its 151st meeting on 8 October 2026, the National Pharmaceutical Pricing Authority (NPPA) approved in principle a cap on trade margins of identified non-scheduled anti-cancer medicines at 30% of MRP
Prices are projected to fall by 20-70%, saving patients about ₹2,500 crore a year; NPPA found an average trade mark-up of about 170%, reaching 700% in some cases
An expert committee under the Directorate General of Health Services (DGHS) will finalise the drug list, after which NPPA issues the notification; manufacturers must keep production at current levels
It widens the February 2019 cap on 42 non-scheduled anti-cancer drugs (526 brands, ₹984 crore a year saved), which used Paragraph 19 of the Drugs (Prices Control) Order, 2013
Trade margin is the gap between the price to stockist (what the maker charges the distributor) and the MRP. Capping it at 30% of MRP equals a mark-up of about 43% on the stockist price. The factory price is left alone; only the supply-chain add-on is limited.
Simple Analogy: A limit on what the shop chain adds, not on the factory price.
Every Drugs (Prices Control) Order is issued under this section; overcharging is recovered under the DPCO read with the Act
Schedule I is the NLEM, whose formulations get NPPA ceiling prices. Non-scheduled drugs are outside ceilings, but their makers may raise MRP by at most 10% a year. Paragraph 19 lets the Government fix the price of any drug in extraordinary circumstances in public interest, the route used for the 2019 cap
384 medicines issued by the Health Ministry in September 2022; this list decides what is 'scheduled'. The cancer drugs now targeted are outside it
Set up on 29 August 1997; fixes and revises drug ceiling prices, enforces DPCO 2013 and recovers overcharged amounts; approved the cancer-drug cap
Created on 1 July 2008 in the Ministry of Chemicals and Fertilizers; NPPA is its attached office
Technical arm of the Ministry of Health and Family Welfare; its expert committee will finalise which cancer drugs are covered
| Aspect | February 2019 | October 2026 |
|---|---|---|
| Drugs covered | 42 selected non-scheduled anti-cancer drugs | Identified non-scheduled anti-cancer drugs on the DGHS committee's list |
| Cap | Trade margin of 30% on MRP | Trade margin of 30% on MRP |
| Price effect | MRPs of 526 brands cut, by up to about 90% | 20-70% reduction expected |
| Annual saving | About ₹984 crore | About ₹2,500 crore expected |
| Status | Notified using Paragraph 19, DPCO 2013 | In-principle approval; notification after the list is final |
GS Paper II > Health - access to medicines; GS Paper III > Economy - price regulation
General Awareness > Government bodies and policies
General Awareness > Regulators and pricing authorities
A medicine in Schedule I of DPCO 2013 (the NLEM), sold at or below the NPPA ceiling price
A medicine outside the NLEM; no ceiling price, but its MRP may rise by at most 10% a year
The difference between the price to stockist and the MRP, shared by distributors and retailers
Extraordinary power to fix or revise the price of any drug in public interest